Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Prestige Consumer Healthcare (PBH) over the last 16 years, with Mar 2025 value amounting to -$182.1 million.

  • Prestige Consumer Healthcare's Cash from Financing Activities fell 46.38% to -$74.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$176.6 million, marking a year-over-year increase of 29.37%. This contributed to the annual value of -$182.1 million for FY2025, which is 24.45% up from last year.
  • Latest data reveals that Prestige Consumer Healthcare reported Cash from Financing Activities of -$182.1 million as of FY2025, which was up 24.45% from -$241.0 million recorded in FY2024.
  • Prestige Consumer Healthcare's 5-year Cash from Financing Activities high stood at -$7.6 million for FY2022, and its period low was -$279.4 million during FY2021.
  • Its 3-year average for Cash from Financing Activities is -$203.0 million, with a median of -$185.8 million in 2023.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 97.29% in 2022, then tumbled by 2,355.36% in 2023.
  • Yearly analysis of 5 years shows Prestige Consumer Healthcare's Cash from Financing Activities stood at -$279.4 million in 2021, then soared by 97.29% to -$7.6 million in 2022, then crashed by 2,355.36% to -$185.8 million in 2023, then dropped by 29.69% to -$241.0 million in 2024, then grew by 24.45% to -$182.1 million in 2025.